128 related articles for article (PubMed ID: 32192567)
1. Newly Approved Novel Dosage Forms of Glucagon for Management of Severe Hypoglycemia.
Borden TJ; Baker DE; Levien TL; Gates BJ
Sr Care Pharm; 2020 Apr; 35(4):176-181. PubMed ID: 32192567
[TBL] [Abstract][Full Text] [Related]
2. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model.
Hinahara J; Weinzimer SA; Bromley ER; Goss TF; Kendall DM; Hammer M
J Manag Care Spec Pharm; 2022 Apr; 28(4):461-472. PubMed ID: 35332789
[No Abstract] [Full Text] [Related]
3. Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study.
Yale JF; Dulude H; Egeth M; Piché CA; Lafontaine M; Carballo D; Margolies R; Dissinger E; Shames AR; Kaplowitz N; Zhang MX; Zhang S; Guzman CB
Diabetes Technol Ther; 2017 Jul; 19(7):423-432. PubMed ID: 28556672
[TBL] [Abstract][Full Text] [Related]
4. Perceptions About Glucagon Delivery Devices for Severe Hypoglycemia: Qualitative Research With Patients, Caregivers, and Acquaintances.
Bajpai SK; Cambron-Mellott MJ; Peck E; Poon JL; Wang Q; Mitchell BD; Babrowicz J; Child CJ; Raibulet NK; Beusterien K
Clin Ther; 2019 Oct; 41(10):2073-2089.e6. PubMed ID: 31526655
[TBL] [Abstract][Full Text] [Related]
5. Glucagon: Its evolving role in the management of hypoglycemia.
Isaacs D; Clements J; Turco N; Hartman R
Pharmacotherapy; 2021 Jul; 41(7):623-633. PubMed ID: 33963599
[TBL] [Abstract][Full Text] [Related]
6. Intranasal Glucagon: A New Way to Treat Hypoglycemic Emergencies.
Lowe RN; Trujillo JM
Ann Pharmacother; 2020 Aug; 54(8):780-787. PubMed ID: 32052651
[No Abstract] [Full Text] [Related]
7. Efficacy and Usability of Intranasal Glucagon for the Management of Hypoglycemia in Patients With Diabetes: A Systematic Review.
Singh-Franco D; Moreau C; Levin AD; Rosa D; Johnson M
Clin Ther; 2020 Sep; 42(9):e177-e208. PubMed ID: 32873417
[TBL] [Abstract][Full Text] [Related]
8. A ready-to-use liquid glucagon for treatment of severe hypoglycemia demonstrates reduced healthcare payer costs in a budget impact model.
Leinwand B; Johnsrud M; Nguyen A; Meyer J; Johnson K
J Med Econ; 2020 Jul; 23(7):744-750. PubMed ID: 32162983
[No Abstract] [Full Text] [Related]
9. NASAL GLUCAGON DELIVERY IS MORE SUCCESSFUL THAN INJECTABLE DELIVERY: A SIMULATED SEVERE HYPOGLYCEMIA RESCUE.
Settles JA; Gerety GF; Spaepen E; Suico JG; Child CJ
Endocr Pract; 2020 Apr; 26(4):407-415. PubMed ID: 32293921
[No Abstract] [Full Text] [Related]
10. New Developments in Glucagon Treatment for Hypoglycemia.
Story LH; Wilson LM
Drugs; 2022 Jul; 82(11):1179-1191. PubMed ID: 35932416
[TBL] [Abstract][Full Text] [Related]
11. Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.
Pöhlmann J; Mitchell BD; Bajpai S; Osumili B; Valentine WJ
J Diabetes Sci Technol; 2019 Sep; 13(5):910-918. PubMed ID: 30700165
[TBL] [Abstract][Full Text] [Related]
12. People With Diabetes and Caregivers Prefer Rescue Glucagon Treatment With a Wider Storage Temperature Range and a Nasal Administration, When Efficacy is Similar: A Discrete Choice Experiment in Spain.
Mitchell BD; Rentz AM; Kummer S; Yan Y; Heidenreich S; Krucien N; Artime E; Osumili B; Rubio M; Gelhorn HL
J Diabetes Sci Technol; 2023 Nov; 17(6):1623-1633. PubMed ID: 35533142
[TBL] [Abstract][Full Text] [Related]
13. Emerging Adult and Caregiver Psychosocial Experiences with Severe Hypoglycemic Events and the Perceived Impact of Nasal Glucagon: A Cross-Sectional Study.
Kelly CS; Nguyen H; Luo W; Chapman K; Poon JL; Perez-Nieves M; Baker L; Wolf WA; Mitchell B
Diabetes Ther; 2023 Aug; 14(8):1285-1298. PubMed ID: 37268778
[TBL] [Abstract][Full Text] [Related]
14. Glucagon delivery - An overview of current and future devices.
Rabinovich A; Priefer R
Diabetes Metab Syndr; 2021; 15(4):102155. PubMed ID: 34198107
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology Update: Emergency Medications for Hypoglycemia in Diabetes.
Schaumleffel C
NASN Sch Nurse; 2021 May; 36(3):149-154. PubMed ID: 33487097
[TBL] [Abstract][Full Text] [Related]
16. Dasiglucagon: A Novel Ready-to-Use Treatment for Severe Hypoglycemia.
Goodhart AL
Ann Pharmacother; 2023 Mar; 57(3):300-305. PubMed ID: 35861467
[TBL] [Abstract][Full Text] [Related]
17. A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting.
Deeb LC; Dulude H; Guzman CB; Zhang S; Reiner BJ; Piché CA; Pradhan S; Zhang XM
Pediatr Diabetes; 2018 Aug; 19(5):1007-1013. PubMed ID: 29512902
[TBL] [Abstract][Full Text] [Related]
18. Needle-free nasal delivery of glucagon for treatment of diabetes-related severe hypoglycemia: toxicology of polypropylene resin used in delivery device.
Reno FE; Edwards CN; Bendix Jensen M; Török-Bathó M; Esdaile DJ; Piché C; Triest M; Carballo D
Cutan Ocul Toxicol; 2016 Sep; 35(3):242-7. PubMed ID: 26426957
[TBL] [Abstract][Full Text] [Related]
19. Usability of Nasal Glucagon Device: Partially Randomized Caregiver and Third-Party User Experience Trial with Simulated Administration at a Japanese Site.
Aranishi T; Nagai Y; Takita Y; Zhang S; Nishimura R
Diabetes Ther; 2020 Jan; 11(1):197-211. PubMed ID: 31686354
[TBL] [Abstract][Full Text] [Related]
20. Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon.
Thieu VT; Mitchell BD; Varnado OJ; Frier BM
Diabetes Obes Metab; 2020 Apr; 22(4):469-479. PubMed ID: 31820562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
